NCT00502294撤回3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Facet Biotech0 个研究点目标入组 150 人开始时间: 2007年7月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 入组人数
- 150
研究概览
简要总结
To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, 18 years of age or older.
- •Diagnosis of UC verified by endoscopy within 60 months prior to consent.
排除标准
- 未提供
研究者
相似试验
终止
2 期
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisUlcerative ColitisNCT00279422Facet Biotech127
终止
3 期
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)GVHDGraft Versus Host DiseaseAcute-graft-versus-host DiseaseAcute GVHDaGVHDNCT05263999Equillium158
已完成
3 期
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantThrombotic MicroangiopathyNCT04543591Alexion Pharmaceuticals, Inc.148
进行中（未招募）
3 期
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative ColitisModerately to Severely Active Ulcerative ColitisNCT03221036Takeda392
已完成
3 期
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.Crohn's DiseaseNCT03234907Takeda215